Literature DB >> 10933375

Results of transvenous occlusion of secundum atrial septal defects with the fourth generation buttoned device: comparison with first, second and third generation devices. International Buttoned Device Trial Group.

P S Rao1, F Berger, C Rey, J Haddad, B Meier, K P Walsh, J S Chandar, T R Lloyd, J S de Lezo, R Zamora, E B Sideris.   

Abstract

OBJECTIVES: The purpose of this study was to assess safety and effectiveness of the fourth generation buttoned device in dosing atrial septal defects (ASDs) and to test the hypothesis that introduction of double button reduces unbuttoning rate without reducing effectiveness.
BACKGROUND: Because of the high unbuttoning rate (7.2%) with first, second and third generation buttoned devices, the device was modified (fourth generation) so that there were two radiopaque spring buttons 4 mm apart on the button loop attached to the occluder.
METHODS: During a four-year period ending in September 1997, 423 patients, ages 1.5 to 80 years (median 16 years), underwent closure of ASD at 40 medical centers around the world.
RESULTS: The ASD size varied between 5 and 30 mm (median 17 mm). The device size varied between 25 and 60 mm. Unbuttoning occurred in 4 (0.9%) of 423 patients. Effective occlusion, defined as no (n = 343) or trivial (n = 34) residual shunt on echo-Doppler studies performed within 24 h of the procedure, was demonstrated in 377 patients (90%). Thus, the unbuttoning rate (0.9 vs. 7.2%) decreased (p<0.01) while effective occlusion rate (90 vs. 92%) remained unchanged (p>0.1) with this device, compared with earlier generation devices. During follow-up from one month to five years (23+/-15 months), 21 (5%) of 417 patients required surgical (n = 12) or transcatheter (n = 9) reintervention, mostly to treat significant residual shunt. In the remaining patients there was gradual reduction and disappearance of the residual shunt. No wire integrity problems were observed.
CONCLUSIONS: These data suggest that the fourth generation buttoned device is as effective as earlier generation devices, but without significant unbuttoning. Follow-up results remained good, with a reintervention-free rate of 89% at five years.

Entities:  

Mesh:

Year:  2000        PMID: 10933375     DOI: 10.1016/s0735-1097(00)00725-7

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  12 in total

1.  Use of the transseptal puncture in transcatheter closure of long tunnel-type patent foramen ovale.

Authors:  C J McMahon; H G El Said; C E Mullins
Journal:  Heart       Date:  2002-08       Impact factor: 5.994

2.  Patent foramen ovale and left atrial appendage: new devices and methods for closure.

Authors:  R Hein; Y Bayard; M Taaffe; F Büscheck; S Ostermayer; K Billinger; M Reschke; T Trepels; H Lissmann-Jensen; K Lang; A Römer; N Wilson; H Sievert
Journal:  Pediatr Cardiol       Date:  2005 May-Jun       Impact factor: 1.655

Review 3.  Patent foramen ovale and atrial septal aneurysm in cryptogenic stroke.

Authors:  Sujoy Ghosh; Arjun Kumar Ghosh; Sandip Kumar Ghosh
Journal:  Postgrad Med J       Date:  2007-03       Impact factor: 2.401

4.  The Journey of an Indian Pediatric Cardiologist : Dr. K. C. Chaudhuri Lifetime Achievement Award/Oration at AIIMS, New Delhi, September 2017.

Authors:  P Syamasundar Rao
Journal:  Indian J Pediatr       Date:  2017-09-27       Impact factor: 1.967

5.  Cribriform amplatzer device closure of fenestrated atrial septal defects: feasibility and technical aspects.

Authors:  Mohammed Numan; Amal El Sisi; Magdi Tofeig; Salwa Gendi; Tohami Tohami; Howaida G El-Said
Journal:  Pediatr Cardiol       Date:  2007-11-13       Impact factor: 1.655

6.  Helex septal occluder: feasibility study of closure of atrial septal defect.

Authors:  Amal Mahmoud El-Sisi; Salwa Gendi; Mohammed Dilawar; Mohamed Numan
Journal:  Pediatr Cardiol       Date:  2007-09-25       Impact factor: 1.655

7.  Community use of the amplatzer atrial septal defect occluder: results of the multicenter MAGIC atrial septal defect study.

Authors:  Allen D Everett; Jacky Jennings; Erica Sibinga; Carl Owada; D Scott Lim; John Cheatham; Ralf Holzer; Jeremy Ringewald; Rani Bandisode; Richard Ringel
Journal:  Pediatr Cardiol       Date:  2008-11-18       Impact factor: 1.655

8.  The gold standard for atrial septal defect closure: current surgical results, with an emphasis on morbidity.

Authors:  R J F Baskett; E Tancock; D B Ross
Journal:  Pediatr Cardiol       Date:  2003 Sep-Oct       Impact factor: 1.655

9.  The use of anticoagulation in pediatric cardiac disease.

Authors:  J R Boris; M A Harris
Journal:  Images Paediatr Cardiol       Date:  2003-07

10.  Feasibility of percutaneous closure of atrial septal defects in adults under transthoracic echocardiography guidance using the Figulla atrial septal defect occluder device.

Authors:  Mahmoud Ali; Hesham Salah El-Din; Sameh Bakhoum; Amal El-Sisi; Kareem Mahmood; Heba Farouk; Hossam Kandil
Journal:  J Saudi Heart Assoc       Date:  2017-04-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.